HeartBeam (NASDAQ: BEAT) has launched a pilot study to evaluate its proprietary on-demand 12-lead ECG patch for detecting coronary artery disease and ischemia—a condition of inadequate blood flow and oxygen supply to tissue. The study marks a critical step in the development of a device that could address a significant gap in cardiac monitoring, as current patch-based ambulatory monitors cannot detect ischemia over extended periods.
Coronary artery disease remains a leading cause of death worldwide, often progressing silently until a major cardiac event. The need for earlier and more accessible detection methods is pressing. HeartBeam’s patch is designed to generate a clinical-grade 12-lead ECG on demand, potentially providing insights that have not been possible with existing continuous monitors or mobile cardiac telemetry (MCT) devices.
“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG could transform how we monitor patients at risk.”
The pilot study will assess the patch’s ability to detect signs of ischemia, which is a common and serious complication of coronary artery disease. If successful, the technology could enter the $2 billion long-term continuous monitor and MCT markets, offering a new tool for clinicians.
HeartBeam’s announcement comes as the company continues to advance its portfolio of cardiac monitoring solutions. The study’s results will help determine the feasibility of the patch for broader clinical use. Further details about the study design and timeline have not been disclosed.
For more information on HeartBeam and its technologies, visit the company’s newsroom at https://ibn.fm/BEAT. The full terms of use and disclaimers are available at http://IBN.fm/Disclaimer.
